MAPT and tauopathy: With a prevalence approaching 20% in individuals over 80,[8a] PART brain samples are relatively accessible and provide an ideal model for studying tau hyperphosphorylation independently of confounding co‐pathologies.[7] Although PART is associated with only mild cognitive decline, its lack of Aβ pathology suggests that PART could serve as a valuable model for identifying therapeutic targets that may have broader applicability across tauopathies.[2a]